NIH Financial Conflict of Interest (FCOI) Policy

The NIH/PHS Financial Conflict of Interest (FCOI) Policy is the federal regulatory framework — codified at 42 CFR Part 50, Subpart F (“Promoting Objectivity in Research”) for grants and cooperative agreements, and the parallel 45 CFR Part 94 for contracts — that requires any institution receiving Public Health Service (PHS) funding, including NIH, to maintain a written FCOI policy, collect financial disclosures from every “Investigator” on a covered project, review and manage any conflict identified, and report it to the funding agency before spending award funds. It is a specific compliance instrument, not a synonym for the general concept of a conflict of interest — an institution can have a mature general COI culture and still be out of compliance with this regulation’s specific procedural and reporting requirements, or vice versa.

What makes something “the NIH/PHS FCOI Policy” rather than a general COI policy

An institutional policy is operating under this specific framework when all of the following are true: (1) the institution receives or applies for PHS funding (grants, cooperative agreements, or contracts); (2) the policy is written and formally adopted, not informal practice; (3) it defines “Investigator” broadly — anyone responsible for the design, conduct, or reporting of the funded research, not only the PI; and (4) it implements the specific procedural elements the regulation requires, distinct from a general-purpose institutional or journal COI policy:

• Significant financial interest (SFI) disclosure, 42 CFR 50.603. Investigators disclose at time of proposal or award, at least annually thereafter, and within 30 days of discovering or acquiring a new SFI. For a publicly traded entity, disclosure is triggered once remuneration in the prior 12 months plus equity value exceeds $5,000; for a non-publicly-traded entity, disclosure is triggered above that same $5,000 remuneration threshold, or if the investigator holds any equity interest at all, regardless of value.
• Institutional review and management, 42 CFR 50.605. A designated official — someone other than the discloser — determines whether a disclosed SFI is related to the PHS-funded research and rises to an FCOI, and, if so, must implement a management plan and report the FCOI to the PHS awarding component before the institution expends any award funds.
• FCOI reporting. Institutions submit an FCOI report to the PHS awarding component before fund expenditure and annually thereafter for the life of the award, describing the nature, approximate value, and relationship of the interest to the funded research, along with the specifics of the management plan.
• Retrospective review. Where an FCOI was not identified or managed in a timely way, the institution must complete a retrospective review — within 120 days of determining noncompliance — documenting the project, methodology, findings, and conclusions, to assess whether research bias occurred.
• Training, 42 CFR 50.604(f). Investigators complete FCOI training before engaging in PHS-funded research and at least every four years afterward, with immediate retraining if the institution substantively revises its policy, a new investigator joins a project, or noncompliance is found.
• Public accessibility. Institutions must make specified FCOI information — the investigator’s name, role, the entity involved, and the approximate dollar value of the interest — available via a publicly accessible website or within five business days of a written request, and retain FCOI records for at least three years from the date the information was most recently updated.

A general institutional or nonprofit-governance COI policy — the kind that applies regardless of funding source — typically covers disclosure and recusal at a much higher level and does not need to meet any of these specific thresholds, timelines, or reporting obligations. See CASRAI’s conflict of interest entry for that broader concept, and the conflict of interest disclosure entry for the disclosure obligation itself, independent of which policy framework triggers it.

Worked examples

Example 1 — equity in a non-publicly-traded company. A principal investigator on an NIH R01 grant holds founder’s equity in a small, non-publicly-traded biotechnology company whose compound is the subject of the funded research. Because the company is not publicly traded, any equity interest at all — regardless of dollar value — meets the SFI disclosure threshold under 42 CFR 50.603. The PI discloses it to the institution; the designated official determines it is directly related to the funded research and constitutes an FCOI; the institution implements a management plan (for example, independent monitoring of the research design and an outside data-analysis review) and reports the FCOI to NIH before spending award funds, consistent with 42 CFR 50.605.

Example 2 — subrecipient institution. A university receives an NIH cooperative agreement and subcontracts part of the work to a second university as a subrecipient. The FCOI regulation’s obligations extend to the subrecipient’s investigators as well — the prime institution must either ensure the subrecipient has its own compliant FCOI policy and receive certification of that fact, or extend its own policy to cover the subrecipient’s investigators, so that disclosures, review, and reporting still occur before subaward funds are expended.

Counter-example

A researcher at the same university receives a private foundation grant with no PHS or NIH funding involved. That project is not subject to 42 CFR Part 50 Subpart F or 45 CFR Part 94 at all — the institution’s general COI policy (and, separately, the foundation’s own disclosure requirements, if any) governs instead. If that same researcher also holds an active NIH award, their FCOI obligations under this policy apply only to the PHS-funded project, not automatically to the foundation-funded one, though many institutions choose to apply one harmonized disclosure process across all funding sources for administrative simplicity — that institutional choice does not change which projects are legally subject to the federal regulation itself.

Frequently asked questions

Is the NIH FCOI Policy the same regulation as 45 CFR Part 94?

No, but they are parallel. 42 CFR Part 50, Subpart F governs PHS grants and cooperative agreements, including most NIH awards; 45 CFR Part 94 imposes an equivalent framework for PHS contracts. Institutions receiving both award types typically maintain one FCOI policy that satisfies both.

Does the $5,000 significant financial interest threshold ever change?

It can — the current $5,000 figure dates to the regulation’s 2011 revision and is set by rulemaking, not by NIH policy guidance alone. Institutions should confirm the current figure directly against 42 CFR 50.603 rather than assume it is permanently fixed.

Who counts as an “Investigator” under this policy?

The regulation defines it broadly: anyone responsible for the design, conduct, or reporting of the PHS-funded research, which typically includes co-investigators and other senior/key personnel, not only the PI named on the Notice of Award.

How is this different from CASRAI’s general “conflict of interest” term?

The general conflict of interest entry covers the underlying concept — what makes an outside interest a conflict, financial vs. non-financial, individual vs. institutional — across research contexts generally, including journal peer review. This entry covers one specific federal compliance framework that applies only to PHS/NIH-funded research: the written-policy requirement, disclosure timing and thresholds, institutional review and reporting duties, and public-accessibility obligations that 42 CFR Part 50 Subpart F and 45 CFR Part 94 impose.

References

• 42 CFR Part 50, Subpart F, “Promoting Objectivity in Research” (PHS financial conflict of interest regulations, 2011 revision) — law.cornell.edu/cfr/text/42/part-50/subpart-F
• 45 CFR Part 94, PHS contracts financial conflict of interest regulations, parallel to 42 CFR Part 50 Subpart F — law.cornell.edu/cfr/text/45/part-94
• 42 CFR 50.605, institutional review, management, and reporting requirements — law.cornell.edu/cfr/text/42/50.605
• NIH Grants Policy Statement, Section 4.1.10, “Financial Conflict of Interest”